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High Efficiency Gene Transfer into
Atherosclerotic Lesions in Hypercholesterolemic
Rabbit Carotid Arteries
Platelet - Stimulated Proliferation of Coronary
Smooth Muscle Cells
I. II. III. IV V
PDGF-BB PDGF-BB PDGF-BB PDGF-BB PLA
+bFGF +bFGF+EGF +bFGF+EGF+ILGF-1
H-SMC 17 ± 6 22 ± 12 22 ± 8 43 ± 13# 73 ± 21*
P-SMC 16 ± 9 23 ± 17 21 ± 11 41 ± 14# 69 ± 16*
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# p < 0.05 vs. I. II and III. *p < 0.05 vs I, II, III and IV
Conclusion: Platelet-induced SMC-PROL in vitro significantly exceeds the
stimulatory effect of individual and combined growth factors suggested to
cause SMC proliferation after coronary angioplasty in vivo. Further studies
need to clarify this effect. which might have important implications for anti-
coagulation during coronary angioplasty.
Human coronary smooth muscle cells (SMC)from atherectomized restenotic
lesions and porcine SMC from lesions 4 weeks after coronary angioplasty
(explant technique) were cultivated to passage 3 to 7. Human platelets (H-
PLA) and porcine platelets (P-PLA) were isolated from citrate-anticoagulated
blood (60 ml, platelet recovery 20 ± 2% of whole blood concentration). SMC
proliferation (PROL) was assessed using 3H-Thymidin incorporation. PROL
following 24 hrs stimulation with 10% fetal calf serum (FCS) averaged 3200
cpm/1 000 SMC and was used as 100% reference for the analysis of platelet-
induced PROL. Both H-PLA and P-PLA stimulated PROL of SMC in a concen-
tration dependent manner with a maximum of 73 ± 21 % (H-PLA, 5 x 104/ILI)
and 69 ± 16% (P-PLA, 22.5 x 104/ILI) of FCS values (mean ± SD). Similar re-
sults were obtained with PLA lysed by sonication. Parallel experiments using
the growth factors PDGF-BB, bFGF, EGF and ILGF-1 alone or in combination
at their maximal effective concentrations showed significantly less stimula-
tion (p < 0.05, AN OVA). PDGF-BB at 50 ng/ml was the most potent stimulat-
ing individual growth factor (17 ± 6% (H-PLA) and 16 ± 9% (P-PLA) of FCS
values.
Results: (PROL-% FCS-values, mean ± SD)
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The feasibility of using in vivo gene transfer to induce the regression of
atherosclerotic lesions remains to be defined. Accordingly, we have devel-
oped a rabbit model of atherosclerosis that consists of (i) a high cholesterol
diet beginning 2 weeks prior to vascular injury (cholesterol levels: 1,000-
2,000 mg/dl), (iii balloon-injury (2 F Fogarty catheter) to the common carotid
artery via the internal carotid artery, and (iii) gene transfer into the vessel wall
2 weeks after balloon injury by a second interventional procedure. Balloon
injury resulted in consistent formation of neointimal lesions (intima/media
ratio: 1.0-1.4; n = 3) throughout the injured vessel segment.
Immunohistochemical staining against macrophages (RAM-ll) showed
a broad distribution of macrophages throughout the neointima and media.
Transfection efficiency into the injured vessel wall was determined using a fJ-
galactosidase (fJ-gal) reporter gene (SV40-promoter) and the highly efficient
Sendai virus (HVJ)-mediated gene delivery method in which plasmid vec-
tors are complexed with Iiposomes, nuclear protein and UV-inactivated viral
protein coat. Histochemical analysis after transfection revealed strong fJ-gal
activity (@ 30-50% of cells transfected) within the neointima and media,
whereas controls (control vector transfected and/or balloon injured vessel)
showed no staining. Double staining with the macrophage antibody showed
that not only smooth muscle cells and fibroblasts, but also macrophages
were genetically modified. We conclude that the rabbit atherosclerotic
carotid artery is a suitable model for studying gene transfer as a therapeutic
approach to vascular disease.
Expression of as!J1 Integrin in Human Vascular
Smooth Muscle Cells: A Potential Mediator for
Vascular Remodeling
An Orally Active Synthetic lib/ilia Receptor
Antagonist Inhibits Ex-vivo Platelet·Thrombus
Formation
J. Geoffrey Pickering, Lawrence H. Chow, Carol M. Ford, Shashi Uniyal, Bosco
M. Chan. Robarts Research Institute and University Hospital, London, Canada
Integrins are heterodimeric (a fJ) cell surface proteins that promote attach-
ment to the extracellular matrix. Their role in vascular lesion formation is un-
known. The a5fJ1 integrin can, however, interact with fibronectin which has
been implicated in lesion formation following vascular injury and can pro-
mote vascular smooth muscle cell (SMC) activation. Therefore, we tested
the hypothesis that SMC activation is functionally linked to a5fJ1 integrin ex-
pression.
To determine which integrins are expressed on human SMCs, cells were
cultivated from internal mammary artery (IMA) and surface-labeled with 1251.
Lysates were immunoprecipitated using a panel of subtype-specific anti-
integrin antibodies. This identified 5 fJ1 integrins: a1 fJl and a2fJl integrins,
which were expressed at relatively low levels, and a3fJl ,a5fJ1 and a6fJ1 inte-
grins which were abundantly expressed. The cellular location of a5fJ1 integrin
was studied by confocal microscopy of SMCs seeded on to fibronectin. This
revealed discrete linear accummulations of the a5 integrin subunit on the
bottom surface of the cell, consistent with focal adhesion plaques. The role
of the "5fJ1 integrin in mediating an interaction with fibronectin was evalu-
ated by adhesion assay. SMCs adhered fully to afibronectin-coated substrate
within 30 min. In contrast, when SMCs were incubated with an anti-<l5 inte-
grin antibody, adherence was reduced by 65% (p < 0.05). Finally, to assess
integrin expression in quiescent SMCs, sections of human IMA were studied
by immunofluorescence microscopy. In contrast to the abundant expression
in activated SMCs proliferating in vitro, quiescent SMCs in the arterial media
stained weakly for a5 integrin.
Conclusion: The a5fJl integrin is selectively expressed in human SMCs
when activated and mediates a functional interaction with fibronectin. This
receptor therefore may be a critical modulator of SMC behavior following
vessel injury.
in oral or IV form, it blocks the final step in platelet activation by blocking
the platelet Gpllbilla, thus protecting against platelet activation by elevated E
and shear stress produced by very severe stenosis. It is also likely to be more
effective than ASA for reducing the platelet contribution to atherosclerosis
preventing coronary thrombosis and fatal or non fatal myocardial infarction
and early and late PMT after angioplasty or atherectomy procedures.
Juan J. Badimon, Beat Meyer, Larry Feigen 1, James Chesebro, Valentin Fuster,
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Coronary artery disease and its progression is clearly linked to thrombosis.
Thrombosis has been successfully inhibited by using several drugs when
given Lv. The use of i.v. drugs is useful to prevent thrombosis in acute sit-
uations; but long-term inhibition of platelet activity will require orally ac-
tive drugs. The available oral agents (ASA, Ticlopidinel have a limited an-
tiplatelet effect. Platelet-fibrinogen binding inhibition by oral administration
of SC-54684A (synthetic mimetic of the RGO-sequence) has been tested as
a strategy to prevent thrombosis. This compound is currently undergoing
clinical trials. Platelet deposition (PO) has been evaluated by 111 In-platelets
in an "ex vivo" canine perfusion model (Badimon's chamberl. Effects of SC-
54684A (3 mglkg; doses that totally block in vitro platelet aggregation) on
PO have been tested on mildly (MI) and severely injured (SI) aortic wall, at
flow conditions modeling shear rates (SR) typical of medium size patent (212
s-l) and stenotic (1690 s-1) arteries after 5 min perfusions. PD results are
expressed as (platelets x 106/cm2) (mean ± SE)
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*p < 0.05
Our results demonstrate that oral administration of a synthetic peptide an-
tagonist of the lib/lila platelet receptor significantly reduces platelet throm-
bus formation on stenosed severely injured lesions where there is a higher
risk of thrombotic occlusions. This novel oral approach may have important
clinical implications.
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Substrate
Flow conditions
Control
SC-54684A
Mild injury
212/s
3.5 ± 0.7
6.2 ± 1.2
1690ls
9.8 ± 32
9.6 ± 1.7
Severe injury
212/s
16.0 ± 3.4
17.2 ± 1.3
1690/s
49.3 ± 4.2
25.8 ± 1.3*
Effects of Hypothyroidism on Neointima
Formation Following Vascular Injury in the Rat
Carotid Artery
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Neointima formation following vascular injury is reduced in hypophysec-
tomized rats indicating that pituitary-derived hormonal factors likely regulate
vascular smooth muscle cell (VSMC) migration and proliferation in vivo. In
order to specifically investigate the role of thyroid hormone in intimal thick-
ening following balloon injury, we made rats hypothyroid by dietary manipu-
